Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find - 2Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- 36 Web-based Staple Help You Can Trust
- 4Remain Cool and Solid: Top Summer Food sources for 2024
- 5Israel reports killing another senior Iranian oil official
- Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.'
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- Grammy nominations 2026: Full list of nominees in every major category, including Album of the Year and Best New Artist
- Dear Santa: I want Botox. Why cosmetic procedures are topping holiday wish lists.
- Iran plans new restrictions in overhaul of Strait of Hormuz rules
- Turkey key underlying issue as Israel, Greece, Cyprus hold summit
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- Netanyahu expects Iran's leadership to fall
- Kuwait is softening stance on Israel, dissident tells ‘Post’ after viral UN speech
